Observation On Curative Effect Of Bifidobacterium Tetragenous Viable Bacteria Tablets And Jinghuaweikang Capsules In The Eradication Of Helicobacter Pylori

Background: A large number of domestic and foreign research datahas shown that Helicobacter pylori （H.pylori） infection is closelyassociated with the occurrence of chronic gastritis, peptic ulcer, gastricMALT lymphoma and gastric cancer. According to statistics, more than50%people worldwide are infected by H.pylori. In recent years, H.pylorieradication failure rate has increased year by year. The main reason isincreased antibiotic resistant trains. The resistance rates of metronidazole,clarithromycin and levofloxacin are60%⁷5%,20%³8%,30%³8%,while the resistance rates of tetracycline, amoxicillin and furazolidone arelow, at an average of1%⁵%. With the increase of drug-resistant strains of H.pylori in these years, the traditional triple therapy eradication rate hasdropped below80%. Moreover there are many adverse reactions, patientswith poor tolerance, easy to relapse and drug resistance problems.Therefore, the search for new choice of initial treatment, to improve theeradication rate of H.pylori has clinical significance.Objective: In this study, Bifidobacterium tetragenous viable bacteriatablets and Jinghuaweikang capsules were used in the eradicate treatmentof H.pylori respectively, which were combined with esomeprazole,clarithromycin and amoxicillin. By observing the H.pylori eradication rate,clinical remission rate and the incidence rate of adverse reaction ofpatients in each group, we explored the clinical efficacy and safety in theeradicate treatment of H.pylori of the two drugs.Methods:100adult patients for treatment in the the gastroenterologyoutpatient department of the Second Hospital of Jilin University from March2012to December2012were selected, who were diagnosedexplicitly H.pylori infection for the first time by the¹⁴C-UBT. There were42male,58female, mean age45.7±10.4（16⁷5） years old. The patientswere randomly divided into3groups for the eradicate treatment ofH.pylori, group A（n=33）: esomeprazole20mg bid, amoxicillin1.0g bid,clarithromycin0.5g bid, treatment for10d; group B（n=34）: esomeprazole20mg bid, amoxicillin1.0g bid, clarithromycin0.5g bid,Bifidobacterium tetragenous viable bacteria tablets1.5g tid, treatment for10d; group C（n=33）: esomeprazole20mg bid, amoxicillin1.0g bid,clarithromycin0.5g bid, Jinghuaweikang capsules160mg tid, treatmentfor10d. The main clinical symptoms, the remission rate, and theincidence rate of adverse reaction in each group were observed. Inaddition, the H.pylori eradication rate was assessed by the¹⁴C-UBT againin all patients4weeks after the treatment. Measurement data was processed using t test, and count data was processed using χ²test. Thedifference was statistically significant when P<0.05.Results:1. The H.pylori eradication rate of Bifidobacterium tetragenous viablebacteria tablets combined with standard triple therapy （test group: group B）was82.4%（28/34）, which was higher than75.8%（25/33） in the controlgroup （test group: group A）, but there was no statistically significantdifference between the two groups （P>0.05）. The clinical symptoms（upper abdominal pain, acid regurgitation, heartburn, abdominal distension）remission rate of group B were90.3%（28/31）,87.5%（21/24）,81.8%（18/22）,85.7%（18/21）, which were higher than63.3%（19/30）,64.0%（16/25）,58.3%（14/24）,54.5%（12/22） in group A, the upperabdominal pain, abdominal distension remission rate of group B beingsignificantly higher than those in group A （P<0.05）, the rest items of group B being no statistically significant difference with those in group A（P>0.05）. There were a few cases of different degrees of adverse reactionsin each group during treatment, mainly upper abdominal discomfort,nausea, taste disorders （bitter taste in the mouth, mouth odor）, diarrhea,insomnia and headache, but there were no serious adverse drug reactions.The incidence rate of adverse reaction of group B was5.9%（2/34）, whichwas significantly lower than39.4%（13/33） in group A （P<0.05）.2. The H.pylori eradication rate of Jinghuaweikang capsules combinedwith standard triple therapy （test group: group C） was87.9%（29/34）,which was higher than that in the control group （test group: group A）, butthere was no statistically significant difference between the two groups（P>0.05）. The clinical symptoms （upper abdominal pain, acidregurgitation, heartburn, abdominal distension） remission rate of group Cwere89.7%（26/29）,89.3%（25/28）,87.5%（21/24）,90.0%（18/20）, which were significantly higher than those in group A （P<0.05）. The incidencerate of adverse reaction of group C was12.1%（4/33）, which wassignificantly lower than that in group A （P<0.05）.Conclusion:1. Both Bifidobacterium tetragenous viable bacteria tablets andJinghuaweikang capsules combined with standard triple therapy,respectively, can improve the rate of H.pylori eradication, but there was nostatistically significant difference compared with the standard tripletherapy.2. Bifidobacterium tetragenous viable bacteria tablets combined withstandard triple therapy, can significantly improve the remission rate ofupper abdominal pain, abdominal distension; and can also ease the acidregurgitation, heartburn, but there was no statistically significantdifference compared with the standard triple therapy. 3. Jinghuaweikang capsules combined with standard triple therapy,can significantly improve the remission rate of upper abdominal pain, acidregurgitation, heartburn, and abdominal distension.4. Both Bifidobacterium tetragenous viable bacteria tablets andJinghuaweikang capsules combined with standard triple therapy,respectively, can significantly reduce the incidence rate of adverse reactionduring treatment.